Zealand Pharma A/S · OMXCOP:ZEAL
Zealand Pharma A/S — Shareholder Meeting (March 2023)
36 slides from Zealand Pharma A/S's shareholder meeting presentation, Mar 29, 2023
Slide 1: Annual General Meeting 2023
Annual General Meeting 2023 Zealand Pharma March 29, 2023
Slide 2: Introduction and report from the Chairman
Introduction and report from the Chairman. Martin Nicklasson Chairman of the Board 2
Slide 3: Forward Looking Statement
Forward Looking Statement This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the informa
Slide 4: Agenda
Agenda 1. Management’s report on the Company's activities during the past financial year 2. Approval of the audited Annual Report 2022 3. Resolution on the cover of loss in accordance with the approved Annual Report 2022 4. Election of members to the Board of Directors 5. Election of the auditor 6.
Slide 5: Agenda: Management's report
Agenda: Management’s report 1. Management’s report on the Company's activities during the past financial year a) Martin Nicklasson (Chairman): Introduction and report from the Chairman b) Adam Steensberg (CEO): Management report for 2022 c) Henriette Wennicke (CFO): Financial highlights 2022 d) Thom
Slide 6: Management report for 2022
Management report for 2022 Adam Steensberg President & Chief Executive Officer 6
Slide 7: In 2022 we delivered on our strategic objectives and achieved significant pipeline progress
In 2022 we delivered on our strategic objectives and achieved significant pipeline progress Announced V-Go® sale strategy to to MannKind Corporate highlights prioritize R&D Zegalogue® partnership and restructure with Novo Nordisk ✓ Implemented operational commercial efficiencies & cost reductions op
Slide 8: Zealand Pharma management
Zealand Pharma management Finance & Business Development Research & Development Adam Steensberg Chief Executive Officer Henriette Wennicke David Kendall Chief Financial Officer Chief Medical Officer People & Organization Operations Legal & IP Christina S. Bredal Ivan M. Møller Ravinder S. Chahil Chi
Slide 9: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product Candidate* Preclinical Phase 1 Phase 2 Phase 3 Registration , diseases Dasiglucagon: S.C. Continuous Infusion Congenital Hyperinsulinism Rare Glepaglutide (GLP-2 Analog) Short Bowel Syndrome BI 456906 (GCGR/GLP-1
Slide 10: In 2023 we have three key strategic objectives focused on maximizing the value potential of our pipeline
In 2023 we have three key strategic objectives focused on maximizing the value potential of our pipeline 1 Progress rare disease assets 2 3 Engage in strategic Advance obesity portfolio toward regulatory filings partnership discussions Dasiglucagon for congenital BI 4569062 (GCGR/GLP-1R) Rare diseas
Slide 11: Financial highlights 2022
Financial highlights 2022 Henriette Wennicke Chief Financial Officer
Slide 12: Profit & Loss
Profit & Loss DKK million 2022 2021 P&L reflecting Zealand’s ambition to be leading peptide drug discovery and development company while commercializing products through partnerships Revenue 104.0 108.5 • Revenue of DKK 104 million in 2022 driven by development agreement with Gross margin 104.0 97.6
Slide 13: Strong cash position allows for investments in R&D
Strong cash position allows for investments in R&D DKK million Cash position of DKK 1,178 million 1.428 1.500 1.178 1,178 842 1.000 1.061 500 469 0 Cash position Cash invested1 Oberland Gross proceeds Cash position 2018 2019 2020 2021 2022 year-end 2021 year-end 2022 Securities Cash & cash equivalen
Slide 14: 2023 financial guidance
2023 financial guidance DKK million 2023 2022 Guidance Actual Revenue anticipated from existing and new license and No guidance 104 partnership agreements due to uncertain size and timing Net operating expenses1 800 - 900 941 Notes 1. Net operating expenses consist of R&D, S&M, G&A and other operati
Slide 15: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 16: Agenda items 1, 2, 3 – Joint Resolutions
Agenda items 1, 2, 3 – Joint Resolutions 1. Management’s report on the Company's activities during the past financial year 2. Approval of the audited Annual Report 2022 3. Resolution on the cover of loss in accordance with the approved Annual Report 2022 16
Slide 17: Agenda item 4: Election of members to the Board of Directors
Agenda item 4 Election of members to the Board of Directors All incumbent board members are standing for re-election and the Board of Directors proposes that in accordance with the recommendation from the Nomination Committee, re-election of all the members: Martin Nicklasson Kirsten A. Drejer Alain
Slide 18: Agenda item 4: Election of members to the Board of Directors
Agenda item 4 Election of members to the Board of Directors All incumbent board members are standing for re-election and the Board of Directors proposes that in accordance with the recommendation from the Nomination Committee, re-election of all the members: Michael J. Owen Leonard Kruimer Bernadett
Slide 19: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 20: Agenda item 5: Election of the auditor
Agenda item 5 Election of the auditor The Board of Directors proposes the re-election of EY Godkendt Revisionspartnerselskab in accordance with the Audit Committee's recommendation. 20
Slide 21: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 22: Agenda item 6: Authorization to acquire treasury shares
Agenda item 6 Authorization for the Company to acquire treasury shares directly The Board of Directors requests that the General Meeting authorizes the Company to acquire, during the period until the next Annual General Meeting, treasury shares directly, provided the acquisition, pursuant to Section
Slide 23: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 24: Agenda item 7: Amend the Remuneration Policy
Agenda item 7 Proposal from the Board of Directors to amend the Company's Remuneration Policy Compared to the existing Remuneration Policy, the revised Remuneration Policy involves the following material amendments: ➢ For the Board of Directors, it was proposed to: o retain the reduced cash element
Slide 25: Agenda item 7: Amend the Remuneration Policy
Agenda item 7 Proposal from the Board of Directors to amend the Company's Remuneration Policy Compared to the existing Remuneration Policy, the revised Remuneration Policy involves the following material amendments: ➢ For the Executive Management, the terms of the long-term incentives are proposed a
Slide 26: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 27: Agenda item 8: Approve the Remuneration Report
Agenda item 8 Proposal from the Board of Directors to approve the Company's Remuneration Report The Board of Directors proposes that the general meeting approves the Company's Remuneration Report for the financial year 2022. The vote on the Remuneration Report is a non-binding advisory vote. 27
Slide 28: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 29: Agenda item 9: Board fees for 2023
Agenda item 9 Proposal by the Board of Directors to approve the fees for the Board of Directors for the financial year 2023 The Board of Directors proposes that the General Meeting approves the fees for the Board of Directors for the financial year 2023: Cash fee (DKK) RSUs (Number) Member of the Bo
Slide 30: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 31: Agenda item 10: Authorization to increase the share capital
Agenda item 10 Proposal from the Board of Directors to approve a new authorization to increase the share capital of the Company by way of cash contribution without pre-emption rights for the Company's existing shareholders and at market price The new authorization shall replace the current authoriza
Slide 32: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 33: Agenda item 11: Renewal of authorization to issue warrants
Agenda item 11 Proposal from the Board of Directors to approve a renewal of the authorization to issue warrants The Board of Directors proposes that the General Meeting adopts a renewal of the applicable authorization for the Board of Directors to issue warrants pursuant to Articles 8.10-8.12 of the
Slide 34: Comments & Questions
ZEALANG) Comments & Questions. = wi
Slide 35: Agenda item 12: Any other business
Agenda item 12 Any other business 35
Slide 36: Thank you
Thank you Zealand Pharma Annual General Meeting March 29, 2023